Folate-Mediated Targeted Delivery of Combination Chemotherapeutics Loaded Reduced Graphene Oxide for Synergistic Chemo-Photothermal Therapy of Cancers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Thapa, Raj Kumar | - |
dc.contributor.author | Choi, Yongjoo | - |
dc.contributor.author | Jeong, Jee-Heon | - |
dc.contributor.author | Youn, Yu Seok | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.contributor.author | Yong, Chul Soon | - |
dc.contributor.author | Kim, Jong Oh | - |
dc.date.accessioned | 2021-06-22T16:01:46Z | - |
dc.date.available | 2021-06-22T16:01:46Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2016-11 | - |
dc.identifier.issn | 0724-8741 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/12553 | - |
dc.description.abstract | Purpose Larger surface area for drug incorporation and superior optical activity makes reduced graphene oxide (rGO) a suitable drug carrier for combination chemotherapeutics delivery. And folate receptors are potential mediators for cancer targeted delivery. This study mainly aimed to prepare irinotecan (IRI)- and docetaxel (DOC)-loaded, folate (FA)-conjugated rGO (FA-P407-rGO/ID) for synergistic cancer therapy. Methods FA-P407-rGO/ID was prepared as aqueous dispersion. Characterization was performed using high performance liquid chromatography (HPLC), transmission electron microscopy (TEM), atomic force microscopy (AFM), ultraviolet/visible spectroscopy, fourier transform infrared spectroscopy (FTIR) and drug release. In vitro cellular studies were performed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), fluorescence-activated cell sorting (FACS) and western blot analyses. Results Our results revealed successful preparation of stable FA-P407-rGO/ID formulation with enhanced drug release profiles in acidic microenvironment. In vitro cytotoxicity of the formulation on folate receptor-expressing human mammary carcinoma (MCF-7) cells was higher than that when free IRI/DOC combination (ID) was used; such increased cytotoxicity was not observed in folate receptor-negative hepatocellular carcinoma (HepG2) cells. Cellular uptake of FA-P407-rGO/ID in MCF-7 cells was higher than in HepG2 cells. Further, FACS and western blot analysis revealed better apoptotic effects of the formulation in MCF-7 cells than in HepG2 cells, suggesting the important role of folate receptors for targeted chemotherapy delivery to cancer cells. Near infrared irradiation further enhanced the apoptotic effect in cancer cells, resulting from the photothermal effects of rGO. Conclusions Hence, FA-P407-rGO/ID can be considered as a potential formulation for folate-targeted chemophotothermal therapy in cancer cells. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER/PLENUM PUBLISHERS | - |
dc.title | Folate-Mediated Targeted Delivery of Combination Chemotherapeutics Loaded Reduced Graphene Oxide for Synergistic Chemo-Photothermal Therapy of Cancers | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Han-Gon | - |
dc.identifier.doi | 10.1007/s11095-016-2007-0 | - |
dc.identifier.scopusid | 2-s2.0-84984659008 | - |
dc.identifier.wosid | 000387394100020 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICAL RESEARCH, v.33, no.11, pp.2815 - 2827 | - |
dc.relation.isPartOf | PHARMACEUTICAL RESEARCH | - |
dc.citation.title | PHARMACEUTICAL RESEARCH | - |
dc.citation.volume | 33 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2815 | - |
dc.citation.endPage | 2827 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | LIQUID-CRYSTALLINE NANOPARTICLES | - |
dc.subject.keywordPlus | AQUEOUS DISPERSIONS | - |
dc.subject.keywordPlus | ANTICANCER DRUGS | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | NANOSHEETS | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | NANOCARRIER | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordAuthor | combination chemotherapy | - |
dc.subject.keywordAuthor | docetaxel | - |
dc.subject.keywordAuthor | folic acid | - |
dc.subject.keywordAuthor | irinotecan | - |
dc.subject.keywordAuthor | reduced graphene oxide | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs11095-016-2007-0 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.